Vibegron — Discount Pricing

Other medications in Urology

• Alfuzosin
• Avanafil
• Bethanechol
• Ciprofloxacin (UTI)
• Desmopressin Nasal
• Doxazosin
• Dutasteride
• Dutasteride/Tamsulosin

About Vibegron

Vibegron (brand name Gemtesa) offers a new approach to managing the challenging symptoms of overactive bladder (OAB). If you're seeking effective treatment, understanding this medication is key. TheDrugClub is here to help make your prescription more affordable, ensuring you have access to the care you need without the prohibitive costs.

What is Vibegron and What Does it Treat?

Vibegron is a prescription medication primarily used to treat overactive bladder (OAB) in adults. OAB is a common condition characterized by a sudden, uncontrollable urge to urinate (urgency), often leading to frequent urination (frequency) and sometimes involuntary loss of urine (urinary incontinence). These symptoms can significantly impact daily life, sleep, and overall quality of life. Vibegron works to alleviate these disruptive symptoms, helping patients regain bladder control and improve their comfort.

How Does Vibegron Work?

Vibegron belongs to a class of drugs called beta-3 adrenergic agonists. Unlike older OAB medications that block certain receptors (anticholinergics), vibegron works by selectively activating beta-3 adrenergic receptors located in the bladder wall. When these receptors are stimulated, the detrusor muscle (the muscle that contracts to empty the bladder) relaxes. This relaxation allows the bladder to hold more urine, reducing the sudden urge to go, decreasing the frequency of urination, and helping prevent leakage. Its unique mechanism of action may offer a different side effect profile compared to anticholinergic medications, which can cause dry mouth, constipation, or blurred vision.

Typical Costs and TheDrugClub Savings

Vibegron (Gemtesa) is a newer, brand-name medication, which typically means it comes with a higher price tag. There is currently no generic version available. Without insurance, or with high-deductible plans, the monthly cost for vibegron can be substantial, often ranging from hundreds of dollars. This can be a significant barrier for many individuals needing this effective treatment.

This is where TheDrugClub steps in. We understand

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Vibegron is approved for (FDA label)

GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. ( 1.1 ) overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). ( 1.2 ) 1.1 Overactive Bladder in Adults GEMTESA ® is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. 1.2 Overactive Bladder in Adult Males with Benign Prostatic Hyperplasia (BPH) GEMTESA is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH).

Source: Read the full FDA label on DailyMed. Label effective date: April 1, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Vibegron (FDA label)

Tablets: 75 mg, oval, light green, film-coated, debossed with V75 on one side and no debossing on the other side. Tablets: 75 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 25f21d25-14f8-4fda-91f6-7aa8b68aa1c8. SPL document ID: 6744a1cf-7abb-4623-85e3-8f67a9eb19d4. Label effective date: April 1, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Vibegron (FDA label)

The following clinically significant adverse reaction is described elsewhere in the labeling: Urinary retention [see Warnings and Precautions ( 5.1 )] Most common adverse reactions (≥2%) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sumitomo Pharma America, Inc. at 1-833-876-8268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 25f21d25-14f8-4fda-91f6-7aa8b68aa1c8. SPL document ID: 6744a1cf-7abb-4623-85e3-8f67a9eb19d4. Label effective date: April 1, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Vibegron (FDA label)

GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of GEMTESA. Hypersensitivity reactions, such as angioedema, have occurred [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )] . Do not use if prior hypersensitivity reaction to vibegron or any components of the product. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 25f21d25-14f8-4fda-91f6-7aa8b68aa1c8. SPL document ID: 6744a1cf-7abb-4623-85e3-8f67a9eb19d4. Label effective date: April 1, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Vibegron (FDA label)

Urinary Retention : Monitor for urinary retention, especially in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for OAB, in whom the risk of urinary retention may be greater.

Source: FDA prescribing information (DailyMed). Set ID: 25f21d25-14f8-4fda-91f6-7aa8b68aa1c8. SPL document ID: 6744a1cf-7abb-4623-85e3-8f67a9eb19d4. Label effective date: April 1, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Vibegron (FDA label)

Concomitant use of GEMTESA increases digoxin maximal concentrations (C max ) and systemic exposure as assessed by area under the concentration-time curve (AUC) [see Clinical Pharmacology ( 12.3 )] . Serum digoxin concentrations should be monitored before initiating and during therapy with GEMTESA and used for titration of the digoxin dose to obtain the desired clinical effect. Continue monitoring digoxin concentrations upon discontinuation of GEMTESA and adjust digoxin dose as needed. Digoxin : Measure serum digoxin concentrations before initiating GEMTESA. Monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect. ( 7 )

Source: FDA prescribing information (DailyMed). Set ID: 25f21d25-14f8-4fda-91f6-7aa8b68aa1c8. SPL document ID: 6744a1cf-7abb-4623-85e3-8f67a9eb19d4. Label effective date: April 1, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.